Exploratory trial to evaluate the risk-benefit ratio of the use of mit
Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Mitoxantrone
What it measured
Main measures
Number of patients withdrawn beacuse of mielotoxicity, cardiotoxicity or severe adverse reactions.
Safety
Who could take part
Relapsing and progressive
Show the full criteria
Inclusion criteria
Inclusion: Patient under treatment with high dose interferon-beta-1a at least for 12 months. Exclusion: Primary progressive multiple sclerosis or secondary progressive without relapses.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the risk-benefit ratio of the treatment with low dose mitoxantrone in patients with high activity multiple sclerosis under treatment with interferon-beta-1a at high dose.
Loading reviews and guidelines…
Related trials
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases
Phase 1 · Recruiting
Still running
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment o
Phase 1 · Recruiting
Still running
- Hydroxychloroquine in progressive MS
Phase 2 · Not yet recruiting
Still running
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and P
Phase 1 · Running, not recruiting
Still running
- A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing
Phase 2 · Withdrawn
Stopped
- Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-a
Early phase 1 · Recruiting
Still running
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Mar 2006